نتایج جستجو برای: ranolazine

تعداد نتایج: 610  

2012
Lars S. Maier

The late Na current is of pathophysiological importance for the heart. Ranolazine is an innovative anti-ischemic and antianginal agent that inhibits the late Na current, thereby reducing the Na-dependent Ca-overload, which improves diastolic tone and oxygen handling during myocardial ischemia. In addition, ranolazine seems to exert beneficial effects on diastolic cardiac function. Moreover, the...

Journal: :Circulation. Heart failure 2017
Raffaele Coppini Luca Mazzoni Cecilia Ferrantini Francesca Gentile Josè Manuel Pioner Annunziatina Laurino Lorenzo Santini Valentina Bargelli Matteo Rotellini Gianluca Bartolucci Claudia Crocini Leonardo Sacconi Chiara Tesi Luiz Belardinelli Jil Tardiff Alessandro Mugelli Iacopo Olivotto Elisabetta Cerbai Corrado Poggesi

BACKGROUND Current therapies are ineffective in preventing the development of cardiac phenotype in young carriers of mutations associated with hypertrophic cardiomyopathy (HCM). Ranolazine, a late Na+ current blocker, reduced the electromechanical dysfunction of human HCM myocardium in vitro. METHODS AND RESULTS To test whether long-term treatment prevents cardiomyopathy in vivo, transgenic m...

Journal: :Circulation. Cardiovascular interventions 2011
Tuomo Nieminen Caio A M Tavares José R M Pegler Luiz Belardinelli Richard L Verrier

BACKGROUND We examined whether intracoronary or intrafemoral administration of ranolazine produces local vasodilation. METHODS AND RESULTS Effects of intra-arterial ranolazine on coronary and femoral artery vasodilation and systemic hemodynamic function were studied in anesthetized pigs (n=27). Ranolazine, nitroglycerin, or saline (control) was injected into the left anterior descending (LAD)...

Journal: :Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2014
Konstantinos C Koskinas Nikolaos Fragakis Demosthenes Katritsis Vassileios Skeberis Vassileios Vassilikos

AIMS Amiodarone is used commonly for pharmacological cardioversion of atrial fibrillation (AF), but it is limited by moderate efficacy and delayed action. Ranolazine and amiodarone are markedly synergistic in suppressing experimental AF in vitro, yet the clinical efficacy of ranolazine combined with amiodarone for AF conversion has only undergone minimal investigation. This prospective, single-...

Journal: :The Journal of pharmacology and experimental therapeutics 2009
Yuzhi Wu Yejia Song Luiz Belardinelli John C Shryock

Palmitoyl-L-carnitine (PC), an ischemic metabolite, causes cellular Na(+) and Ca(2+) overload and cardiac dysfunction. This study determined whether ranolazine [(+/-)-1-piperazineacetamide, N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-] attenuates PC-induced Na(+) current and ventricular contractile dysfunction of the isolated heart. PC (4 microM, 30 min) increased late Na(+)...

Journal: :Journal of the American College of Cardiology 2010
Alexander Burashnikov Serge Sicouri José M Di Diego Luiz Belardinelli Charles Antzelevitch

OBJECTIVES The aim of this study was to evaluate the effectiveness of a combination of dronedarone and ranolazine in suppression of atrial fibrillation (AF). BACKGROUND Safe and effective pharmacological management of AF remains one of the greatest unmet medical needs. METHODS The electrophysiological effects of dronedarone (10 μmol/l) and a relatively low concentration of ranolazine (5 μmo...

Journal: :acta physiologica hungarica 2014
h khazraei m shafa h mirkhani

ranolazine is a new antianginal drug that is postulated to act through blocking of cardiac late sodium channels and improvement in cardiac blood flow. the present study has been carried out to investigate its possible effect on microcirculation of normal and diabetic rats’ cardiac muscle. methods: normal and diabetic rats were anesthetized. the chest was opened and a surface laser doppler flowm...

Journal: :Circulation. Arrhythmia and electrophysiology 2015
James A Reiffel A John Camm Luiz Belardinelli Dewan Zeng Ewa Karwatowska-Prokopczuk Ann Olmsted Wojciech Zareba Spencer Rosero Peter Kowey

BACKGROUND Atrial fibrillation (AF) requires arrhythmogenic changes in atrial ion channels/receptors and usually altered atrial structure. AF is commonly treated with antiarrhythmic drugs; the most effective block many ion channels/receptors. Modest efficacy, intolerance, and safety concerns limit current antiarrhythmic drugs. We hypothesized that combining agents with multiple anti-AF mechanis...

Journal: :Circulation research 2003
Alan MacInnes David A Fairman Peter Binding Jo ann Rhodes Michael J Wyatt Anne Phelan Peter S Haddock Eric H Karran

Trimetazidine acts as an effective antianginal clinical agent by modulating cardiac energy metabolism. Recent published data support the hypothesis that trimetazidine selectively inhibits long-chain 3-ketoacyl CoA thiolase (LC 3-KAT), thereby reducing fatty acid oxidation resulting in clinical benefit. The aim of this study was to assess whether trimetazidine and ranolazine, which may also act ...

2014
Chunyun Du Yihong Zhang Aziza El Harchi Christopher E. Dempsey Jules C. Hancox

The antianginal drug ranolazine, which combines inhibitory actions on rapid and sustained sodium currents with inhibition of the hERG/IKr potassium channel, shows promise as an antiarrhythmic agent. This study investigated the structural basis of hERG block by ranolazine, with lidocaine used as a low potency, structurally similar comparator. Recordings of hERG current (IhERG) were made from cel...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید